16-fraction postmastectomy RT noninferior for reconstruction

Editor's Pick: Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) (Journal of Clinical Oncology, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning breast cancer radiation, ablation and screening, the reach of germline testing, and a wave of novel targeted agents across gynaecologic, genitourinary and rarer tumours. Let's dive in.
This week's papers:
• Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42863096)
• NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42842849)
• Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42854706)
• Universal Germline Genetic Testing after a Diagnosis of Cancer. — Cancer Discovery 2026 (pubmed.ncbi.nlm.nih.gov/42844684)
• Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42843394)
• Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42849725)
• Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42848391)
• Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42854175)
• VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42868322)
• RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42848980)
Listen at AudioScholar (audioscholar.cc/episode/swnfuv2tsd)